


PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:
KIM, Eui-Bak

The Cheonghwa Bldg. 1571-18 Seocho-dong, Seocho-gu
Seoul 137-874, Republic of Korea



PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Applicant's or agent's file reference
LG-22414-PCT

Date of mailing
(day/month/year) 11 MARCH 2005 (11.03.2005)

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/KR2004/001647

International filing date (day/month/year)
03 JULY 2004 (03.07.2004)

Priority date(day/month/year)
12 JUNE 2004 (12.06.2004)

International Patent Classification (IPC) or both national classification and IPC

IPC7 B01J 27/14

Applicant

LG CHEM. LTD. et al

1. This opinion contains indications relating to the following items:

<input checked="" type="checkbox"/>	Box No. I	Basis of the opinion
<input type="checkbox"/>	Box No. II	Priority
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/>	Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/>	Box No. VI	Certain documents cited
<input type="checkbox"/>	Box No. VII	Certain defects in the international application
<input type="checkbox"/>	Box No. VIII	Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/KR

 Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, SI GEUN

Telephone No. 82-42-481-8151



WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/KR2004/001647

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

a sequence listing
 table(s) related to the sequence listing

b. format of material

in written format
 in computer readable form

c. time of filing/furnishing

contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.

3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2004/001647

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

1. Statement

Novelty (N)	Claims	1 - 12	YES
	Claims		NO
Inventive step (IS)	Claims	1 - 12	YES
	Claims		NO
Industrial applicability (IA)	Claims	1 - 12	YES
	Claims		NO

2. Citations and explanations :

The following document has been considered for the purpose of this opinion.

D1 : US 5,233,093 A

The present invention relates to a catalyst composition comprising bidentate ligand including bis-aryl phosphine compound, monodentate ligand such as triphenyl phosphine oxide, etc., and a catalyst having transition metals such as Co, Rh etc., and a process of hydroformylating an olefin compound by using the same.

D1 is considered to represent the most relevant state of the art. It relates to a hydroformylation method of allyl alcohol by using a catalyst composition comprising bidentate ligand such as bisdiphenylphosphinobutane, etc., monodentate ligand such as triphenyl phosphine, etc., and a catalyst having transition metals such as Rh, Ru etc.

I. Novelty and Inventive Step

D1 does not disclose the present hydroformylation method of olefin by using a catalyst composition containing bidentate ligand of formula 1 in claim 1 having bis-aryl phosphine compound and monodentate ligand such as triphenyl phosphine oxide, etc. In addition, the catalyst composition including said phosphine and phosphine oxide is not considered to be easily invented from the invention disclosed in D1 by a person skilled in the art.

II. Industrial Applicability

There is no reason for forming a negative opinion about the industrial applicability of this invention. Consequently, claims 1 to 12 appear to meet the requirement of PCT Article 33(4).